Radius Pharma sells off part of its royalties, milestones in breast cancer drug Orserdu
2023-08-14
引进/卖出
Radius Pharmaceuticals is pulling in an upfront payment of $130 million from DRI Healthcare as part of a royalty purchase agreement for its breast cancer drug elacestrant, the Boston-based biotech announced Monday.
Radius Pharmaceuticals, a subsidiary of Radius Health, could also receive another $10 million from DRI if “certain events” happen. Radius will keep more than $200 million in potential commercial milestones from the Menarini Group, which snagged global commercial and development rights to elacestrant for only $30 million in July 2020.
Preview
来源: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。